Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors [clinicaltrials:NCT00006036]
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors [clinicaltrials:NCT00006036]
Bio2RDF identifier
NCT00006036
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00006036
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... d or metastatic solid tumors.
brief title [clinicaltrials_vocabulary:brief-title]
Liposomal Lurtotecan Plus Cisp ...... ced or Metastatic Solid Tumors
completion date [clinicaltrials_vocabulary:completion-date]
2009-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... dy within 12-15
months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-07-05T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
borderline ovarian surface epithelial-stromal tumor
extensive stage small cell lung cancer
ovarian sarcoma
ovarian stromal cancer
recurrent adenoid cystic carcinoma of the oral cavity
recurrent basal cell carcinoma of the lip
recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
recurrent inverted papilloma of the paranasal sinus and nasal cavity
recurrent lymphoepithelioma of the nasopharynx
recurrent lymphoepithelioma of the oropharynx
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-11-07T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00006036
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study of NX 211 in C ...... in Patients With Solid Tumors
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
CAN-NCIC-IND133
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2000-04-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-03-01T00:00:00Z
identifier
clinicaltrials:NCT00006036
title
Liposomal Lurtotecan Plus Cisp ...... ced or Metastatic Solid Tumors
@en
type
label
Liposomal Lurtotecan Plus Cisp ...... s [clinicaltrials:NCT00006036]
@en